866-997-4948(US-Canada Toll Free)

Ureter Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Apr 2016

Category :

Cancer

No. of Pages : 98 Pages

Ureter Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Ureter Cancer - Pipeline Review, H1 2016, provides an overview of the Ureter Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ureter Cancer
- The report reviews pipeline therapeutics for Ureter Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ureter Cancer therapeutics and enlists all their major and minor projects
- The report assesses Ureter Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ureter Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ureter Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ureter Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ureter Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Ureter Cancer Overview 7
Pipeline Products for Ureter Cancer Comparative Analysis 8
Ureter Cancer Therapeutics under Development by Companies 9
Ureter Cancer Therapeutics under Investigation by Universities/Institutes 10
Ureter Cancer Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Ureter Cancer Products under Development by Companies 14
Ureter Cancer Products under Investigation by Universities/Institutes 15
Ureter Cancer Companies Involved in Therapeutics Development 16
Altor BioScience Corporation 16
Eisai Co., Ltd. 17
Exelixis, Inc. 18
Merck & Co., Inc. 19
Ureter Cancer Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ALT-801 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cabozantinib s-malate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
eribulin mesylate - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pembrolizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PGV-001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Ureter Cancer Recent Pipeline Updates 55
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables
Number of Products under Development for Ureter Cancer, H1 2016 7
Number of Products under Development for Ureter Cancer Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Ureter Cancer Pipeline by Altor BioScience Corporation, H1 2016 16
Ureter Cancer Pipeline by Eisai Co., Ltd., H1 2016 17
Ureter Cancer Pipeline by Exelixis, Inc., H1 2016 18
Ureter Cancer Pipeline by Merck & Co., Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Ureter Cancer Therapeutics Recent Pipeline Updates, H1 2016 55

List of Figures
Number of Products under Development for Ureter Cancer, H1 2016 7
Number of Products under Development for Ureter Cancer Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *